SpyGlass Pharma, Inc. - Asset Resilience Ratio
SpyGlass Pharma, Inc. (SGP) has an Asset Resilience Ratio of 9.56% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read SGP current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how SpyGlass Pharma, Inc.'s Asset Resilience Ratio has changed over time. See SGP total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down SpyGlass Pharma, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SpyGlass Pharma, Inc. (SGP) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $11.08 Million | 9.56% |
| Total Liquid Assets | $11.08 Million | 9.56% |
Asset Resilience Insights
- Limited Liquidity: SpyGlass Pharma, Inc. maintains only 9.56% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
SpyGlass Pharma, Inc. Industry Peers by Asset Resilience Ratio
Compare SpyGlass Pharma, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 33.70% |
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392 |
Biotechnology | 11.64% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 2.21% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 82.25% |
Annual Asset Resilience Ratio for SpyGlass Pharma, Inc. (2023–2025)
The table below shows the annual Asset Resilience Ratio data for SpyGlass Pharma, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.56% | $11.08 Million | $115.87 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $23.32 Million | -- |
| 2023-12-31 | 59.46% | $24.47 Million | $41.15 Million | -- |
About SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intra… Read more